Nuheara Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

Nuheara heeft een totaal eigen vermogen van A$5.1M en een totale schuld van A$2.4M, wat de schuld-eigenvermogensverhouding op 46.3% brengt. De totale activa en totale passiva bedragen respectievelijk A$13.0M en A$7.9M.

Belangrijke informatie

46.3%

Verhouding schuld/eigen vermogen

AU$2.37m

Schuld

Rente dekkingsratio	n/a
Contant	AU$2.32m
Aandelen	AU$5.11m
Totaal verplichtingen	AU$7.91m
Totaal activa	AU$13.02m

Recente financiële gezondheidsupdates

Recent updates

Does Nuheara (ASX:NUH) Have A Healthy Balance Sheet?

Oct 09

Here's Why Nuheara (ASX:NUH) Must Use Its Cash Wisely

Jul 30

Here's Why Nuheara (ASX:NUH) Must Use Its Cash Wisely

Apr 13

We Think Nuheara (ASX:NUH) Needs To Drive Business Growth Carefully

Dec 24

Is Nuheara (ASX:NUH) In A Good Position To Deliver On Growth Plans?

Aug 25

What Can We Make Of Nuheara's (ASX:NUH) CEO Compensation?

Jan 14

Is Nuheara (ASX:NUH) Using Debt In A Risky Way?

Nov 22

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( A$8.0M ) NUH } overtreffen de korte termijn passiva ( A$3.1M ).

Langlopende schulden: De kortetermijnactiva NUH ( A$8.0M ) overtreffen de langetermijnschulden ( A$4.8M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 0.9% ) NUH wordt als voldoende beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van NUH is de afgelopen 5 jaar gestegen van 0% naar 46.3%.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: Er zijn onvoldoende gegevens om te bepalen of NUH voldoende cash runway heeft op basis van de huidige vrije kasstroom.

Voorspelling contante baan: Er zijn onvoldoende gegevens om te bepalen of NUH voldoende cash runway heeft als de vrije kasstroom blijft groeien of krimpen op basis van historische percentages.

Nuheara Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Does Nuheara (ASX:NUH) Have A Healthy Balance Sheet?

Here's Why Nuheara (ASX:NUH) Must Use Its Cash Wisely

Here's Why Nuheara (ASX:NUH) Must Use Its Cash Wisely

We Think Nuheara (ASX:NUH) Needs To Drive Business Growth Carefully

Is Nuheara (ASX:NUH) In A Good Position To Deliver On Growth Plans?

Is Nuheara (ASX:NUH) Using Debt In A Risky Way?

Recent updates

Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 1.850332 million.

Nuheara Limited Announces the Retirement of David Cannington as Non-Executive Director

Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 3.929624 million.

New major risk - Shareholder dilution

Does Nuheara (ASX:NUH) Have A Healthy Balance Sheet?

Full year 2023 earnings released: AU$0.084 loss per share (vs AU$0.16 loss in FY 2022)

Nuheara Limited, Annual General Meeting, Nov 22, 2023

New major risk - Financial position

Nuheara Limited Announces Appointment of Catherine Morgan as Head of Compliance, Regulatory and Legal

New minor risk - Share price stability

Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 4.4 million.

First half 2023 earnings released: AU$0.048 loss per share (vs AU$0.065 loss in 1H 2022)

Insufficient new directors

Nuheara Announces Commercial Availability of HP Hearing PRO OTC Hearing Aid

Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 3.025401 million.

Nuheara Limited Receives US FDA Approval and Launches HP Hearing PRO

Nuheara Limited to Report Q1, 2023 Results on Oct 31, 2022

Nuheara Limited Announces the Resignation of Jean-Marie Rudd as CFO

Full year 2022 earnings released: AU$0.16 loss per share (vs AU$0.10 loss in FY 2021)

Nuheara Limited, Annual General Meeting, Nov 29, 2022

Full year 2022 earnings released: AU$0.15 loss per share (vs AU$0.093 loss in FY 2021)

Nuheara Limited Welcomes US Food and Drug Administration's Final Ruling, Establishing A Regulatory Category for Over-The-Counter (Otc) Hearing Aids in the United States

Here's Why Nuheara (ASX:NUH) Must Use Its Cash Wisely

Nuheara Limited Announces Executive Changes

Nuheara Limited has filed an IPO in the amount of AUD 5 million.

Here's Why Nuheara (ASX:NUH) Must Use Its Cash Wisely

Nuheara Submits 510(k) for U.S. FDA Clearance

Nuheara Announces Executive Changes

Nuheara Limited Announces Successful Clinical Trial Self-Fitted Hearing Aids

Nuheara Limited to Report Q2, 2022 Results on Jan 31, 2022

Nuheara Clinical Trial and FDA 510(K) Pathway Update

We Think Nuheara (ASX:NUH) Needs To Drive Business Growth Carefully

Nuheara Limited Provides Update on Clinical Trial and Pathway to FDA 510(K) Approval

Is Nuheara (ASX:NUH) In A Good Position To Deliver On Growth Plans?

Full year 2021 earnings released: AU$0.005 loss per share (vs AU$0.011 loss in FY 2020)

Nuheara Limited Receives U.S. FDA Registration and Hearing Aid Device Listing

First half 2021 earnings released: AU$0.001 loss per share (vs AU$0.006 loss in 1H 2020)

What Can We Make Of Nuheara's (ASX:NUH) CEO Compensation?

Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 11.5 million.

Nuheara Limited announced that it expects to receive AUD 11.5 million in funding

Nuheara Limited Appoints Warwick Sauer as Director

Is Nuheara (ASX:NUH) Using Debt In A Risky Way?

Nuheara Receives $2 Million Phase II Works with HP Inc

Full year earnings released - AU$0.011 loss per share

Nuheara Limited announced that it has received funding

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven